AA Amyloidosis Clinical Trial
Official title:
An Open-label Single Center, Single Patient Study of an Experimental Antisense Oligonucleotide (ASO) Treatment in AA Amyloidosis
The purpose of this study is to assess the safety and efficacy of a subcutaneous injection of nL-SAA1-01in a patient with AA Amyloidosis.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06354322 -
Unclassified GENotypes of Autoinflammatory Diseases and AA Amyloidosis
|
||
Completed |
NCT02704065 -
Recurrent AA Amyloidosis After Renal Transplantation
|
N/A |